Dublin, Feb. 18, 2020 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.
One of the key objectives of the report was to estimate the existing market size and the future opportunity for bispecific antibody therapeutics, for the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the evolution of the market for the period 2019-2030.
The report also features the likely distribution of the current and forecasted opportunity across:
- Key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders),
- Different mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others),
- Key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1 x IL-1, Psl x PcrV, TNF- x HSA and VEGF-A x ANG-2),
- Type of antibody formats (asymmetric, fragments, symmetric and others),
- Key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical)
- Key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Amongst other elements, the report includes:
- A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment.
- A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above)development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain.
- Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available).
- Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, [B] a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size.
- An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and, target therapeutic area.
- An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals.
- A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO.
- A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial.
- A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto and Hemlibra. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences.
- A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.
The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
- Martin Steiner (Chief Executive Officer, Synimmune)
- Ludger Groe-Hovest (Chief Scientific Officer, Synimmune)
- Jane Dancer (Chief Business Officer, F-Star)
- Siobhan Pomeroy (Senior Director, Business Development, Cytom X)
- Yinjue Wang (Associate Director, Process Development, Innovent Biologics)
Companies Mentioned
- 3P Biopharmaceuticals
- Ab Studio
- AbbVie
- AbCellera
- AbClon
- ABL Bio
- Ablynx
- Abpro
- Abveris
- Abzena
- Abzyme Therapeutics
- Adicet Bio
- Adimab
- Advaxis
- Affibody
- Affimed
- AGC Biologics
- Agensys
- Agenus
- AgonOx
- Akeso Biopharma
- Alcami
- Aldevron
- Alexion Pharmaceuticals
- Alissa Pharma
- Allergan
- Alligator Bioscience
- Alphamab Oncology
- Altor BioScience
- Ambrx
- Amgen
- Amunix
- AnaptysBio
- Anogen
- Antibody Solutions
- AP Biosciences
- Aptevo Therapeutics
- ARBELE
- Array BioPharma (Now acquired by Pfizer)
- Astellas Pharma
- AstraZeneca
- Atreca
- AURA Biotechnologies
- Avacta
- AvantGen
- Avidity Biosciences
- Avillion
- Axcellerate Pharma
- Baliopharm
- Barbara Ann Karmanos Cancer Institute
- Bayer
- BeiGene
- Benhealth Biopharmaceutical
- Betta Pharmaceuticals
- BioFactura
- BioInvent
- BIOMUNEX Pharmaceuticals
- BioNTech
- Bio-Synthesis
- Biotecnol
- Biotest
- Biotheus
- BiVictriX Therapeutics
- bluebird bio
- Boehringer Ingelheim
- Brigham and Women's Hospital (BWH)
- Bristol-Myers Squibb
- Calico
- Cancer Research UK
- Catalent Biologics
- Celgene
- CELLSCRIPT
- Celonic
- Centre Leon Berard
- ChemPartner
- Chiome Bioscience
- Christian Doppler (CD) Laboratory
- Chugai Pharmaceutical
- CinnaGen
- CMC Biologics
- Cobra Biologics
- Compass Therapeutics
- Complix
- Covagen
- Creative Biolabs
- Creative Biostructure
- Crescendo Biologics
- CStone Pharmaceuticals
- CytomX Therapeutics
- Cytovance Biologics
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- DCPrime
- Denali Therapeutics
- Dong-A ST
- Dragonfly Therapeutics
- Dualogics
- Eddingpharm
- Eli Lilly
- EMD Serono
- Emergent BioSolutions
- EnGeneIC
- EngMab
- EpimAb Biotherapeutics
- Exelixis
- F-star
- Fuda Cancer Hospital
- FUJIFILM Diosynth Biotechnologies
- Fusion Antibodies
- FZata
- GEMoaB
- Genedata
- Genentech
- GENERON
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Glycotope
- GO Therapeutics
- Goodwin Biotechnology
- Greffex
- Gritstone Oncology
- GT Biopharma
- GTP Technology
- Gustave Roussy
- Hanmi Pharmaceutical
- Harbour BioMed
- Harpoon Therapeutics
- HEC Paris
- Henlix Biotech
- ICON
- IGM Biosciences
- I-Mab Biopharma
- Immatics
- Immune Biosolutions
- Immune Design
- Immune Pharmaceuticals
- Immunex
- ImmuNext
- Immunocore
- Immunomedics
- Incyte
- Inhibrx
- Innate Pharma
- Innovent Biologics
- Inovio Pharmaceuticals
- Institute for Research in Biomedicine (IRB) Barcelona
- Invenra
- IONTAS
- IQVIA
- Janssen
- Johnson & Johnson
- Just mention University of California San Diego
- JW Pharmaceutical
- Kaken Pharmaceutical
- KBI Biopharma
- Kymab
- Lava Therapeutics
- Lazarex Cancer Foundation
- LeadArtis
- LEO Pharma
- LG Chem Life Sciences
- LifeArc
- Ligand Pharmaceuticals
- Light Chain Bioscience
- Lonza
- Luye Pharma Group
- M2Gen
- MAB Discovery
- MabPlex
- MabVax Therapeutics
- MacroGenics
- Massachusetts General Hospital (MGH)
- MediaPharma
- MedImmune
- Memorial Sloan Kettering Cancer Center
- Merck
- Mereo BioPharma
- Meridian Life Science
- Merrimack Pharmaceuticals
- Merus
- Millegen
- MilliporeSigma
- Molecular Partners
- MorphoSys
- Morphotek
- NanoString
- Nantes University Hospital
- National Cancer Institute (NCI)
- National Institutes of Health
- Navarrabiomed
- Neovii Biotech
- NextCure
- NJCTTQ
- Northwestern University
- Novartis
- Novasep
- Novimmune
- Numab
- OncoMed Pharmaceuticals
- Ono Pharmaceutical
- OriMAbs
- OSE Immunotherapeutics
- Ossianix
- Pfizer
- PharmAbcine
- Pieris Pharmaceuticals
- Pierre Fabre
- Premas Biotech
- ProMab Biotechnologies
- Provention Bio
- Pure Biologics
- Pure MHC
- PX'Therapeutics
- QIMR Berghofer Medical Research Institute
- Regeneron Pharmaceuticals
- Rentschler Biotechnologie
- Rice University
- Roche
- Roger Williams Medical Center
- Sanofi
- SATT Sud-Est
- Sea Lane Biotechnologies
- Seattle Genetics
- Selexis
- SemaThera
- SENJU Pharmaceutical
- Servier
- Simcere
- Sound Biologics
- Stanford University
- Sutro Biopharma
- Swedish Orphan Biovitrum (Sobi)
- Syapse
- Synimmune
- SystImmune
- Taisho Pharmaceutical
- Takara Bio
- Takeda Pharmaceutical
- Tango Therapeutics
- Tasly Biopharma
- Tempus
- TeneoBio
- TESARO
- TG Therapeutics
- The Hebrew University of Jerusalem
- The Institute for Protein Design (IPD)
- The Johns Hopkins University School of Medicine
- The University of Texas MD Anderson Cancer Center
- The Wistar Institute
- Theradex Oncology
- Tilos Therapeutics
- TOT BIOPHARM
- TRACON Pharmaceuticals
- Trianni
- TRIGR Therapeutics
- Tufts University School of Medicine
- UCLA AIDS Institute
- University of California
- University of Chicago
- University of Kentucky Markey Cancer Center
- University of Michigan
- University of Minnesota
- University of North Carolina
- University of Virginia
- University of Zurich
- Vall d'Hebron Institute of Oncology
- Weizmann Institute of Science
- Wisconsin Alumni Research Foundation
- WuXi AppTec
- WuXi Biologics
- Xencor
- XOMA
- Y-Biologics
- Y-mAbs Therapeutics
- Yuhan
- YUMAB
- YZY Biopharma
- Zai Lab
- Zebra Biologics
- Zhejiang Teruisi Biopharmaceutical
- Zymeworks
- Zyngenia
For more information about this report visit https://www.researchandmarkets.com/r/u6avb5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900